MedPath

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Phase 3
Recruiting
Conditions
Venous Thromboembolism
Deep Venous Thrombosis
Pulmonary Embolism
Interventions
Registration Number
NCT05171075
Lead Sponsor
Anthos Therapeutics, Inc.
Brief Summary

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Detailed Description

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. Patients with intact GI and GU cancer have increased bleeding risk with oral direct anticoagulants (DOACs), Guidelines advice caution with those DOACs or state preference for low molecular weight heparin (LMWH) in this population. The ANT-008 study will compare treatment with abelacimab monthly administration to LMWH daily subcutaneous (sc) administration over 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1020
Inclusion Criteria
  • Male or female subjects ≥18 years old or other legal maturity age according to the country of residence

  • Confirmed GI (colorectal, pancreatic, gastric, esophageal, gastro-esophageal junction or hepatobiliary) or confirmed GU (renal, ureteral, bladder, prostate, or urethra) cancers if:

    • Unresectable, locally advanced, metastatic, or non-metastatic GI/GU cancer and
    • No intended curative surgery during the study
  • Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava vein thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery. Patients are eligible within 120 hours from diagnosis of the qualifying VTE.

  • Anticoagulation therapy with LMWH for at least 6 months is indicated

  • Able to provide written informed consent

Read More
Exclusion Criteria
  • Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) occurrence of DVT and/or PE
  • More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, or other anticoagulants
  • An indication to continue treatment with therapeutic doses of an anticoagulant other than for VTE treatment prior to randomization (e.g., atrial fibrillation, mechanical heart valve, prior VTE)
  • PE leading to hemodynamic instability (systolic BP <90 mmHg or shock).
  • Acute ischemic or hemorrhagic stroke or intracranial hemorrhage, in the last 4 weeks preceding screening.
  • Brain trauma, or cerebral or a spinal cord surgery or spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening
  • Need for aspirin in a dosage of more than 100 mg/day or, any other antiplatelet agent alone or in combination with aspirin
  • Bleeding requiring medical attention at the time of randomization or in the preceding 4 weeks
  • Planned brain, spinal cord, cardiac, vascular, major thoracic and/or major abdominal surgery in the 4 weeks following randomization
  • History of heparin induced thrombocytopenia
  • Infective acute or subacute endocarditis at the time of presentation
  • Primary brain cancer or untreated intracranial metastasis
  • Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 at screening
  • Life expectancy of <3 months at randomization
  • Calculated creatinine clearance (CrCl) <30 mL/min at the screening visit
  • Platelet count <50,000/ mm3 at the screening visit
  • Hemoglobin <8 g/dL at the screening visit
  • Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase ≥3 times and/or bilirubin ≥2 times the upper limit of normal (ULN) at the screening visit in the absence of clinical explanation
  • Uncontrolled hypertension (systolic blood pressure [BP] > 180 mm Hg or diastolic BP >100 mm Hg despite antihypertensive treatment)
  • Women of child-bearing potential (WOCBP) who are unwilling or unable to use highly effective contraceptive measures during the study from screening up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab
  • Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab
  • Pregnant or breast-feeding women
  • History of hypersensitivity to any of the study drugs (including dalteparin) or its excipients, to drugs of similar chemical classes, or any contraindication listed in the label for dalteparin
  • Subjects with any condition that in the judgement of the Investigator would place the subject at increased risk of harm if he/she participated in the study
  • Use of other investigational (not-registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies, comprising testing different strategies or different combinations of registered drugs is permitted.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
DalteparinDalteparinDalteparin administered subcutaneously daily
AbelacimabAbelacimabAbelacimab intravenous administration followed by monthly administration of the same dose subcutaneously
Primary Outcome Measures
NameTimeMethod
Time to first event of centrally adjudicated VTE recurrence consisting of new proximal deep venous thrombosis, new pulmonary embolism (PE) or fatal PE, including unexplained death for which PE cannot be ruled out6 months
Secondary Outcome Measures
NameTimeMethod
Time to first event of ISTH-adjudicated major or clinically relevant non-major (CRNM) bleeding events6 months
Net clinical benefit defined as survival without VTE recurrence, or major or CRNM bleeding6 months

Trial Locations

Locations (179)

Southern Medical University - Zhujiang Hospital

🇨🇳

Guangdong, China

University of Colorado Anschutz Medical Campus

🇺🇸

Aurora, Colorado, United States

Washington DC VAMC

🇺🇸

Washington, District of Columbia, United States

University of Miami Health System/Sylvester Comprehensive Cancer Center

🇺🇸

Miami, Florida, United States

Winship Cancer Institute of Emory University

🇺🇸

Atlanta, Georgia, United States

NorthShore University Health System

🇺🇸

Evanston, Illinois, United States

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Barnes-Jewish Hospital

🇺🇸

Saint Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center-Middletown

🇺🇸

Middletown, New Jersey, United States

Memorial Sloan Kettering Cancer Center-Commack

🇺🇸

Commack, New York, United States

Memorial Sloan Kettering Cancer Center-West Harrison

🇺🇸

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

🇺🇸

New York, New York, United States

Weill Cornell Medical College

🇺🇸

New York, New York, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

University of Pennsylvania - Penn Blood Disorders Center

🇺🇸

Philadelphia, Pennsylvania, United States

Temple University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

University of Texas Mays Cancer Center

🇺🇸

San Antonio, Texas, United States

Blacktown Hospital

🇦🇺

Blacktown, New South Wales, Australia

Westmead Hospital

🇦🇺

Westmead, New South Wales, Australia

Box Hill Hospital

🇦🇺

Box Hill, Victoria, Australia

Northern Health

🇦🇺

Epping, Victoria, Australia

Concord Repatriation General Hospital

🇦🇺

Concord, Australia

Perth Blood Institute

🇦🇺

Perth, Australia

The Alfred Hospital

🇦🇺

Prahran, Australia

LKH - Universitätsklinikum Graz

🇦🇹

Graz, Austria

LK Wiener Neustadt

🇦🇹

Neustadt, Austria

Medical University of Vienna

🇦🇹

Vienna, Austria

Hamilton Health Sciences, Juravinski Hospital and Cancer Centre

🇨🇦

Hamilton, Ontario, Canada

Ottawa Hospital Research Instituite

🇨🇦

Ottawa, Ontario, Canada

Niagara Health System

🇨🇦

Saint Catharines, Ontario, Canada

Jewish General Hospital

🇨🇦

Montréal, Quebec, Canada

McGill University Health Centre

🇨🇦

Montréal, Quebec, Canada

University of Calgary

🇨🇦

Calgary, Canada

Sault Area Hospital

🇨🇦

Marie, Canada

Toronto General Hospital

🇨🇦

Toronto, Canada

Beijing Shijitan Hosp.

🇨🇳

Beijing, China

Peking University Third Hospital

🇨🇳

Beijing, China

Jilin Province Tumor Hospital

🇨🇳

Ch'ang-ch'un, China

Nanfang Hospital of Southern Medical University

🇨🇳

Guangzhou, China

The Sixth Affiliated Hospital of Sun Yat-Sen University

🇨🇳

Guangzhou, China

Huizhou Municipal Central Hospital

🇨🇳

Huizhou, China

Nanjing First Hospital

🇨🇳

Nanjing, China

Nantong Tumor Hospital (Tumor Hospital Affiliated to Nantong University )

🇨🇳

Tongzhou, China

The First Affiliated Hospital of Wenzhou Medical University

🇨🇳

Wenzhou, China

Union Hospital Tongji Medical College Huazhong University of Science &Technology

🇨🇳

Wuhan, China

Hubei Cancer Hospital

🇨🇳

Wuhan, China

The Second Hospital of Jiaxing

🇨🇳

Zhejiang, China

Masarykuv onkologicky ustav

🇨🇿

Brno, Czechia

University Hospital Hradec Kralove

🇨🇿

Hradec Králové, Czechia

Nemocnice Na Pleši s.r.o.

🇨🇿

Nová Ves Pod Pleší, Czechia

Onkologická klinika VFN a 1. LF UK

🇨🇿

Prague, Czechia

Thomayerova nemocnice

🇨🇿

Praha, Czechia

CHU de Brest - Hôpital de la Cavale Blanche

🇫🇷

Brest, Cedex, France

CHU de Limoges - Hôpital Dupuytren

🇫🇷

Limoges, France

CH Le Puy en Velay

🇫🇷

Le Puy-en-Velay, Chantemesse, France

Hôpital Louis Mourier

🇫🇷

Colombes, Renouiflers, France

CHU de Nancy - Hôpital de Brabois Adultes

🇫🇷

Vandœuvre-lès-Nancy, France

CHU Amiens - Hopital Nord

🇫🇷

Amiens, France

CHU Angers - Hôpital Hôtel Dieu

🇫🇷

Angers, France

CHU Clermont Ferrand - Hopital Gabriel Montpied

🇫🇷

Clermont-Ferrand, France

CHU Dijon - Hôpital Bocage Central

🇫🇷

Dijon, France

CHU de Grenoble - Hôpital Albert Michallon

🇫🇷

Grenoble, France

Hopital Timone Adultes

🇫🇷

Marseille, France

Groupe Hospitalier Pitie-Salpetriere

🇫🇷

Paris, France

Hôpital Européen Georges Pompidou

🇫🇷

Paris, France

Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud

🇫🇷

Pierre-Bénite, France

CHU de Rouen - Hôpital de Bois Guillaume

🇫🇷

Rouen, France

CHU de Saint-Etienne - Hopital Nord

🇫🇷

Saint-Étienne, France

CHU Strasbourg - Nouvel Hôpital Civil

🇫🇷

Strasbourg, France

Nouvel Hôpital Civil de Strasbourg

🇫🇷

Strasbourg, France

Centre Hospitalier Intercommunal de Toulon

🇫🇷

Toulon, France

Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt

🇩🇪

Dresden, Germany

Universitaetsklinikum Carl Gustav Carus TU Dresden

🇩🇪

Dresden, Germany

Praxis für Gefäßmedizin

🇩🇪

Görlitz, Germany

Universitaetsklinikum Hamburg-Eppendorf

🇩🇪

Hamburg, Germany

Universitätsklinik der Christian-Albrechts-Universität

🇩🇪

Kiel, Germany

Universitätsklinik Leipzig

🇩🇪

Leipzig, Germany

Orszagos Onkologiai Intezet

🇭🇺

Budapest, Hungary

Debreceni Egyetem

🇭🇺

Debrecen, Hungary

Bacs-Kiskun County Hospital

🇭🇺

Kecskemét, Hungary

University of Pécs

🇭🇺

Pécs, Hungary

Cork University Hospital

🇮🇪

Cork, Ireland

Bon Secour Hospital

🇮🇪

Cork, Ireland

Beaumont Hospital

🇮🇪

Dublin, Ireland

Markhot Ferenc Oktatokorhaz es Rendelointezet

🇭🇺

Eger, Hungary

University Hospital, Limerick

🇮🇪

Limerick, Ireland

IRCCS Istituto Tumori Giovanni Paolo II

🇮🇹

Bari, Italy

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

🇮🇹

Bergamo, Italy

Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia

🇮🇹

Reggio Emilia, Italy

Presidio Ospedaliero di Castelfranco Veneto

🇮🇹

Castelfranco Veneto, Italy

SS. ma Annunziata

🇮🇹

Chieti, Italy

Ospedale Civile Dell Annunziata

🇮🇹

Cosenza, Italy

Ospedale Degli Infermi

🇮🇹

Faenza, Italy

Azienda Ospedaliero Universitaria San Martino

🇮🇹

Genova, Italy

Presidio Ospedaliero della Misericordia

🇮🇹

Grosseto, Italy

Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo

🇮🇹

Milano, Italy

A.O.U. Policlinico di Modena

🇮🇹

Modena, Italy

Istituto Nazionale Tumori Fondazione G. Pascale

🇮🇹

Napoli, Italy

Azienda Ospedale - Università Padova

🇮🇹

Padova, Italy

Ospedale Universitario

🇮🇹

Padova, Italy

Azienda Ospedaliero Universitaria di Parma

🇮🇹

Parma, Italy

Universit degli Studi di Perugia - Azienda Ospedaliera di Perugia

🇮🇹

Perugia, Italy

Azienda Ospedaliero Universitaria Pisana

🇮🇹

Pisa, Italy

Fondazione Policlinico Universitario A. Gemelli IRCCS.

🇮🇹

Roma, Italy

Istituto Clinico Humanitas

🇮🇹

Rozzano, Italy

Ospedale Santa Maria di Cà Foncello

🇮🇹

Treviso, Italy

Azienda Ospedaliero-Universitaria Santa Maria della Misericordia

🇮🇹

Udine, Italy

Università dell'Insubria

🇮🇹

Varese, Italy

Ospedale SS. Giovanni e Paolo

🇮🇹

Venezia, Italy

Ospedalemichele e Pietro ferrer

🇮🇹

Verduno, Italy

Ospedale San Bortolo di Vicenza

🇮🇹

Vicenza, Italy

Hallym University Sacred Heart Hospital

🇰🇷

Anyang-Si, Korea, Republic of

SoonChunHyang University Hospital Bucheon

🇰🇷

Bucheon, Korea, Republic of

Dong-A University Hospital

🇰🇷

Pusan, Korea, Republic of

Daegu Catholic University Medical Center

🇰🇷

Daegu, Korea, Republic of

Yongin Severance Hospital, Yonsei University Health System

🇰🇷

Gyeonggi-do, Korea, Republic of

Myongji Hospital

🇰🇷

Jeonju, Korea, Republic of

Jeonbuk National University Hospital

🇰🇷

Jeonju, Korea, Republic of

Soonchunhyang University Seoul Hospital

🇰🇷

Seoul, Korea, Republic of

Kyung Hee University Hospital at Gangdong

🇰🇷

Seoul, Korea, Republic of

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Korea, Republic of

Ewha Womans University Mokdong Hospital

🇰🇷

Seoul, Korea, Republic of

Daugavpils Regional Hospital

🇱🇻

Daugavpils, Latvia

Liepaja Regional Hospital

🇱🇻

Liepāja, Latvia

Pauls Stradins CUH

🇱🇻

Riga, Latvia

Riga East Clinical University Hospital

🇱🇻

Riga, Latvia

Meander Medisch Centrum

🇳🇱

Amersfoort, Netherlands

Onze Lieve Vrouwe Gasthuis, Locatie Oost

🇳🇱

Amsterdam, Netherlands

Rode Kruis Ziekenhuis

🇳🇱

Beverwijk, Netherlands

Haga Ziekenhuis

🇳🇱

Den Haag, Netherlands

Albert Schweitzer Ziekenhuis, Dordwijk

🇳🇱

Dordrecht, Netherlands

Universitair Medisch Centrum Groningen

🇳🇱

Groningen, Netherlands

Spaarne Gasthuis (Kennemer Gasthuis) - Haarlem-Zuid

🇳🇱

Haarlem, Netherlands

Tergooiziekenhuizen, Hilversum

🇳🇱

Hilversum, Netherlands

Amsterdam University Medical Center

🇳🇱

Holland, Netherlands

Leids Universitair Medisch Centrum

🇳🇱

Leiden, Netherlands

Radboud Universitair Medisch Centrum

🇳🇱

Nijmegen, Netherlands

Ikazia Ziekenhuis

🇳🇱

Rotterdam, Netherlands

Østfold Hospital Kalnes

🇳🇴

Fredrikstad, Norway

Akershus Univeristy Hospital

🇳🇴

Lørenskog, Norway

Oslo University Hospital, Dep of Haematology

🇳🇴

Oslo, Norway

Hospital Universitario Del Vinalopo

🇪🇸

Alicante, Spain

Complejo Hospital Vall D'Hebron

🇪🇸

Barcelona, Spain

Hospital Clinic de Barcelona

🇪🇸

Barcelona, Spain

Hospital de la Santa Creu I Sant Pau

🇪🇸

Barcelona, Spain

Hospital Universitario Reina Sofia

🇪🇸

Córdoba, Spain

Hospital General Universitario de Elche

🇪🇸

Elche, Spain

Hospital Universitario Virgen de las Nieves

🇪🇸

Granada, Spain

Hospital Universitario Ciudad de Jaen

🇪🇸

Jaén, Spain

Hospital Universitario Lucus Augusti

🇪🇸

Lugo, Spain

Hospital General Universitario Gregorio Marañon

🇪🇸

Madrid, Spain

Clinica Universidad de Navarra

🇪🇸

Pamplona, Spain

Hospital Universitario Infanta Leonor

🇪🇸

Madrid, Spain

MD Anderson Cancer Centre

🇪🇸

Madrid, Spain

Hospital Universitario Puerta de Hierro Majadahonda

🇪🇸

Majadahonda, Spain

Hospital Universitario Virgen del Rocio

🇪🇸

Sevilla, Spain

Complejo Hospitalario Universitario de Ourense

🇪🇸

Ourense, Spain

Hospital Universitario Central de Asturia

🇪🇸

Oviedo, Spain

Corporacio Sanitaria Parc Tauli

🇪🇸

Sabadell, Spain

Hospital Universitario Marques de Valdecilla

🇪🇸

Santander, Spain

Complejo Hospitalario Universitario de Santiago

🇪🇸

Santiago De Compostela, Spain

Länssjukhuset Sundsvall-Härnösand

🇸🇪

Sundsvall, Sweden

Hopital Universitaire Geneve

🇨🇭

Geneve, Switzerland

University of Zürich

🇨🇭

Zürich, Switzerland

Kaohsiung Medical University Chung-Ho Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

Far Eastern Memorial Hospital

🇨🇳

New Taipei City, Taiwan

China Medical University Hospital

🇨🇳

Taichung, Taiwan

Taichung Veterans General Hospital

🇨🇳

Taichung, Taiwan

National Cheng Kung University (NCKU) Hospital

🇨🇳

Tainan, Taiwan

Koo Foundation Sun Yat-Sen Cancer Center

🇨🇳

Taipei, Taiwan

Tri-Service General Hospital

🇨🇳

Taipei, Taiwan

University Hospital of Wales

🇬🇧

Cardiff, England, United Kingdom

Barts Health NHS Trust

🇬🇧

London, England, United Kingdom

Castle Hill Hospital, Department of Oncology & Haematology

🇬🇧

Cottingham, ENG, United Kingdom

The Newcastle Upon Tyne Hospitals

🇬🇧

Newcastle Upon Tyne, ENG, United Kingdom

Queen Elizabeth University Hospital Campus

🇬🇧

Glasgow, SCO, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath